Cargando…
Development of Novel Heparin/Protamine Nanoparticles Useful for Delivery of Exogenous Proteins In Vitro and In Vivo
We previously reported that heparin/protamine particles (LHPPs) produced as nanoparticles through simple mixing of raw materials exhibit sustained protein release and can be retained in cells. In the present study, we modified LHPPs without employing any organic synthetic approach. The resulting LHP...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466629/ https://www.ncbi.nlm.nih.gov/pubmed/32806578 http://dx.doi.org/10.3390/nano10081584 |
_version_ | 1783577857558052864 |
---|---|
author | Nakamura, Shingo Ando, Naoko Ishihara, Masayuki Sato, Masahiro |
author_facet | Nakamura, Shingo Ando, Naoko Ishihara, Masayuki Sato, Masahiro |
author_sort | Nakamura, Shingo |
collection | PubMed |
description | We previously reported that heparin/protamine particles (LHPPs) produced as nanoparticles through simple mixing of raw materials exhibit sustained protein release and can be retained in cells. In the present study, we modified LHPPs without employing any organic synthetic approach. The resulting LHPPs were re-named as improved LHPPs (i-LHPPs) and have the ability to retain cell-penetrating peptides (GRKKRRQRRRPPQ) based on electrostatic interactions. We examined whether i-LHPPs can introduce exogenous proteins (i.e., lacZ protein encoding bacterial β-galactosidase) into cultured cells in vitro, or into murine hepatocytes in vivo through intravenous injection to anesthetized mice. We found an accumulation of the transferred protein in both in vitro cultured cells and in vivo hepatocytes. To the best of our knowledge, reports of successful in vivo delivery to hepatocytes are rare. The i-LHPP-based protein delivery technique will be useful for in vivo functional genetic modification of mouse hepatocytes using Cas9 protein-mediated genome editing targeting specific genes, leading to the creation of hepatic disease animal models for research that aims to treat liver diseases. |
format | Online Article Text |
id | pubmed-7466629 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74666292020-09-14 Development of Novel Heparin/Protamine Nanoparticles Useful for Delivery of Exogenous Proteins In Vitro and In Vivo Nakamura, Shingo Ando, Naoko Ishihara, Masayuki Sato, Masahiro Nanomaterials (Basel) Communication We previously reported that heparin/protamine particles (LHPPs) produced as nanoparticles through simple mixing of raw materials exhibit sustained protein release and can be retained in cells. In the present study, we modified LHPPs without employing any organic synthetic approach. The resulting LHPPs were re-named as improved LHPPs (i-LHPPs) and have the ability to retain cell-penetrating peptides (GRKKRRQRRRPPQ) based on electrostatic interactions. We examined whether i-LHPPs can introduce exogenous proteins (i.e., lacZ protein encoding bacterial β-galactosidase) into cultured cells in vitro, or into murine hepatocytes in vivo through intravenous injection to anesthetized mice. We found an accumulation of the transferred protein in both in vitro cultured cells and in vivo hepatocytes. To the best of our knowledge, reports of successful in vivo delivery to hepatocytes are rare. The i-LHPP-based protein delivery technique will be useful for in vivo functional genetic modification of mouse hepatocytes using Cas9 protein-mediated genome editing targeting specific genes, leading to the creation of hepatic disease animal models for research that aims to treat liver diseases. MDPI 2020-08-12 /pmc/articles/PMC7466629/ /pubmed/32806578 http://dx.doi.org/10.3390/nano10081584 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Nakamura, Shingo Ando, Naoko Ishihara, Masayuki Sato, Masahiro Development of Novel Heparin/Protamine Nanoparticles Useful for Delivery of Exogenous Proteins In Vitro and In Vivo |
title | Development of Novel Heparin/Protamine Nanoparticles Useful for Delivery of Exogenous Proteins In Vitro and In Vivo |
title_full | Development of Novel Heparin/Protamine Nanoparticles Useful for Delivery of Exogenous Proteins In Vitro and In Vivo |
title_fullStr | Development of Novel Heparin/Protamine Nanoparticles Useful for Delivery of Exogenous Proteins In Vitro and In Vivo |
title_full_unstemmed | Development of Novel Heparin/Protamine Nanoparticles Useful for Delivery of Exogenous Proteins In Vitro and In Vivo |
title_short | Development of Novel Heparin/Protamine Nanoparticles Useful for Delivery of Exogenous Proteins In Vitro and In Vivo |
title_sort | development of novel heparin/protamine nanoparticles useful for delivery of exogenous proteins in vitro and in vivo |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466629/ https://www.ncbi.nlm.nih.gov/pubmed/32806578 http://dx.doi.org/10.3390/nano10081584 |
work_keys_str_mv | AT nakamurashingo developmentofnovelheparinprotaminenanoparticlesusefulfordeliveryofexogenousproteinsinvitroandinvivo AT andonaoko developmentofnovelheparinprotaminenanoparticlesusefulfordeliveryofexogenousproteinsinvitroandinvivo AT ishiharamasayuki developmentofnovelheparinprotaminenanoparticlesusefulfordeliveryofexogenousproteinsinvitroandinvivo AT satomasahiro developmentofnovelheparinprotaminenanoparticlesusefulfordeliveryofexogenousproteinsinvitroandinvivo |